{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:50:43Z","timestamp":1774536643899,"version":"3.50.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cjca.2017.04.015","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T21:45:37Z","timestamp":1493934337000},"page":"883-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy"],"prefix":"10.1016","volume":"33","author":[{"given":"Haran","family":"Yogasundaram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2017.04.015_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10741-015-9524-5","article-title":"Melas syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis","volume":"21","author":"Hsu","year":"2016","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjca.2017.04.015_bib2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra0902923","article-title":"Inherited cardiomyopathies","volume":"364","author":"Watkins","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib3","doi-asserted-by":"crossref","first-page":"e003367","DOI":"10.1161\/CIRCHEARTFAILURE.116.003367","article-title":"Glycogen storage disease because of a prkag2 mutation causing severe biventricular hypertrophy and high-grade atrio-ventricular block","volume":"9","author":"Yogasundaram","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.04.015_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in fos - Fabry outcome survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjca.2017.04.015_bib8","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase a gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-014-9452-9","article-title":"Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment","volume":"20","author":"Putko","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cjca.2017.04.015_bib10","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMcps1209279","article-title":"Clinical problem-solving. In the thick of it","volume":"368","author":"Rao","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib11","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2017.04.015_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2017.04.015_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.04.015_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J\u00a0Hum Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A\u00a0systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"van der Tol","year":"2014","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib19","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.04.015_bib20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype1","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2017.04.015_bib21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","article-title":"Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics","volume":"68","author":"Favalli","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib25","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.04.015_bib26","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib27","first-page":"1","article-title":"Cardiac manifestation of Fabry disease from hypertrophic cardiomyopathy to early diagnosis and treatment in patients without left ventricular hypertrophy","volume":"4","author":"Fern\u00e1ndez","year":"2016","journal-title":"J\u00a0Inborn Errors Metab Screen"},{"key":"10.1016\/j.cjca.2017.04.015_bib28","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jacc.2013.08.1644","article-title":"The moge(s) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation","volume":"62","author":"Arbustini","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2017.04.015_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1012428009627","article-title":"Cardiac manifestations in Fabry disease","volume":"24","author":"Linhart","year":"2001","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/eurjhf\/hft104","article-title":"Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease","volume":"15","author":"Tomberli","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"suppl 2","key":"10.1016\/j.cjca.2017.04.015_bib31","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/01.ASN.0000016683.73778.78","article-title":"Natural history and treatment of renal involvement in Fabry disease","volume":"13","author":"Branton","year":"2002","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2017.04.015_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","article-title":"Fabry's disease","volume":"344","author":"El-Abassi","year":"2014","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.cjca.2017.04.015_bib33","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"Scheidt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2017.04.015_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000060194","article-title":"A\u00a0new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant","author":"Germain","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.cjca.2017.04.015_bib37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease (alpha-galactosidase a deficiency): renal involvement and enzyme replacement therapy","author":"Desnick","year":"2001","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.cjca.2017.04.015_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2215\/CJN.05570809","article-title":"Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy","volume":"5","author":"Mignani","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2017.04.015_bib39","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jmedgenet-2011-100407","article-title":"Fabry international prognostic index: a predictive severity score for Anderson-Fabry disease","volume":"49","author":"Hughes","year":"2012","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib42","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2016.01.076","article-title":"Constrictive pericarditis versus restrictive cardiomyopathy?","volume":"67","author":"Garcia","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib43","doi-asserted-by":"crossref","first-page":"e0140627","DOI":"10.1371\/journal.pone.0140627","article-title":"Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy","volume":"10","author":"Kramer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2017.04.015_bib44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1067\/mhj.2000.105105","article-title":"New insights in cardiac structural changes in patients with Fabry's disease","volume":"139","author":"Linhart","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib45","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in Fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib46","series-title":"Fabry Disease: Perspectives From 5 Years of Fos","first-page":"198","article-title":"The heart in Fabry disease","author":"Linhart","year":"2006"},{"key":"10.1016\/j.cjca.2017.04.015_bib47","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/08035320510028049","article-title":"The right ventricle in Fabry disease","volume":"94","author":"Kampmann","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.cjca.2017.04.015_bib50","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.echo.2008.09.002","article-title":"Right ventricular involvement in Fabry disease","volume":"21","author":"Palecek","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib51","doi-asserted-by":"crossref","first-page":"e0157565","DOI":"10.1371\/journal.pone.0157565","article-title":"Reduced right ventricular native myocardial t1 in Anderson-Fabry disease: comparison to pulmonary hypertension and healthy controls","volume":"11","author":"Pagano","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2017.04.015_bib52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.04.015_bib53","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.carpath.2009.05.003","article-title":"A\u00a0detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy","volume":"19","author":"Sheppard","year":"2010","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.cjca.2017.04.015_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ultrasmedbio.2010.10.017","article-title":"Prominent papillary muscles in Fabry disease: a diagnostic marker?","volume":"37","author":"Niemann","year":"2011","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.cjca.2017.04.015_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCHEARTFAILURE.108.769729","article-title":"Angina in Fabry disease reflects coronary small vessel disease","volume":"1","author":"Chimenti","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.04.015_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CRD.0b013e31818adc50","article-title":"Fabry disease: cardiac manifestations and therapeutic options","volume":"17","author":"Pierre-Louis","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cjca.2017.04.015_bib58","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/CIRCULATIONAHA.114.012178","article-title":"Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy","volume":"130","author":"Frustaci","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10545-013-9607-1","article-title":"Early cardiovascular remodelling in Fabry disease","volume":"37","author":"Costanzo","year":"2014","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib60","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","article-title":"Timi frame count: a quantitative method of assessing coronary artery flow","volume":"93","author":"Gibson","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib61","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.ijcard.2013.12.060","article-title":"Stable microvascular angina: instrumental evaluation of coronary microvascular dysfunction with coronary angiography and myocardial scintigraphy","volume":"171","author":"Sucato","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib62","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.CIR.100.22.2219","article-title":"Effect of potential confounding factors on the thrombolysis in myocardial infarction (TIMI) trial frame count and its reproducibility","volume":"100","author":"Abaci","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib63","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacc.2004.05.048","article-title":"Coronary flow velocity reserve does not correlate with TIMI frame count in patients undergoing non-emergency percutaneous coronary intervention","volume":"44","author":"Chugh","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib64","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijcard.2014.11.026","article-title":"Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease","volume":"177","author":"Spinelli","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-7120-3-11","article-title":"Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic doppler echocardiography","volume":"3","author":"Dimitrow","year":"2005","journal-title":"Cardiovasc Ultrasound"},{"key":"10.1016\/j.cjca.2017.04.015_bib66","first-page":"473","article-title":"The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift","volume":"38","author":"Crea","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib67","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1093\/eurheartj\/ehv100","article-title":"Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation","volume":"36","author":"Pries","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib68","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2010.07.016","article-title":"When should cardiologists suspect Anderson-Fabry disease?","volume":"106","author":"Gambarin","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/8904_2015_502","article-title":"Electrical changes in resting, exercise, and Holter electrocardiography in Fabry cardiomyopathy","volume":"28","author":"Kramer","year":"2016","journal-title":"JIMD Rep"},{"key":"10.1016\/j.cjca.2017.04.015_bib70","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib71","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000047318","article-title":"Ventricular fibrillation refractory to automatic internal cardiac defibrillator in Fabry's disease. Review of cardiovascular manifestations","volume":"94","author":"Eckart","year":"2000","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2017.04.015_bib72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kramer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib74","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib75","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib77","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib78","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.cjca.2017.04.015_bib79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib80","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cjca.2014.08.016","article-title":"Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment","volume":"30","author":"Yogasundaram","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib81","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1399-0004.1982.tb02080.x","article-title":"Pseudodeficiency of alpha-galactosidase A","volume":"21","author":"Bach","year":"1982","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2017.04.015_bib84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib85","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib86","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2016.06.026","article-title":"Challenges in the diagnosis of Anderson-Fabry disease: a deceptively simple and yet complicated genetic disease","volume":"68","author":"Marian","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib87","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2011.05.008","article-title":"Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a \u201csequencing cryptic\u201d alpha-galactosidase a large deletion","volume":"104","author":"Feldt-Rasmussen","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2017.04.015_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ejhf.230","article-title":"Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease","volume":"17","author":"Hollander","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2017.04.015_bib89","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib90","doi-asserted-by":"crossref","first-page":"e002528","DOI":"10.1161\/CIRCHEARTFAILURE.115.002528","article-title":"Established and emerging roles of biomarkers in heart failure clinical trials","volume":"9","author":"Ibrahim","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.04.015_bib91","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex","volume":"6","author":"Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib92","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib93","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","article-title":"Early detection of Fabry cardiomyopathy by tissue Doppler imaging","volume":"107","author":"Pieroni","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib95","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCIMAGING.111.968859","article-title":"Exercise response in hypertrophic cardiomyopathy: blunted left ventricular deformational and twisting reserve with altered systolic-diastolic coupling","volume":"5","author":"Soullier","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib96","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/eurheartj\/eht098","article-title":"Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease","volume":"34","author":"Kr\u00e4mer","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib97","first-page":"50","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.echo.2016.10.014","article-title":"Impaired left atrial function in Fabry disease: a longitudinal speckle-tracking echocardiography study","volume":"30","author":"Pichette","year":"2017","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib99","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2006.07.088","article-title":"Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease","volume":"99","author":"Kawano","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.04.015_bib100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.echo.2011.05.021","article-title":"Tei index in Fabry disease","volume":"24","author":"Niemann","year":"2011","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib102","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib103","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.04.015_bib104","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/echo.13367","article-title":"Differential diagnosis of left ventricular hypertrophy: usefulness of multimodality imaging and tissue characterization with cardiac magnetic resonance","volume":"33","author":"Izgi","year":"2016","journal-title":"Echocardiography"},{"key":"10.1016\/j.cjca.2017.04.015_bib105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib106","doi-asserted-by":"crossref","first-page":"W97","DOI":"10.2214\/AJR.08.1201","article-title":"Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy","volume":"192","author":"De Cobelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cjca.2017.04.015_bib107","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","article-title":"The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease","volume":"8","author":"Moon","year":"2006","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.cjca.2017.04.015_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.cjca.2017.04.015_bib109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10545-005-0563-2","article-title":"Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease","volume":"28","author":"Kalliokoski","year":"2005","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib111","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00259-015-3036-3","article-title":"First experience of simultaneous PET\/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease","volume":"42","author":"Nappi","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib112","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1161\/CIRCULATIONAHA.105.584292","article-title":"Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease","volume":"113","author":"Hasegawa","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib113","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib114","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry Disease Initiative","volume":"111","author":"Sirrs","year":"2014","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cjca.2017.04.015_bib115","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Group","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib116","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/ehjci\/jev057","article-title":"Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease","volume":"16","author":"Putko","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.04.015_bib117","author":"Sirrs"},{"key":"10.1016\/j.cjca.2017.04.015_bib118","doi-asserted-by":"crossref","first-page":"e003259","DOI":"10.1161\/JAHA.116.003259","article-title":"Growing evidence linking microvascular dysfunction with heart failure with preserved ejection fraction","volume":"5","author":"Giamouzis","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2017.04.015_bib119","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.04.015_bib121","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A\u00a0phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib122","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib123","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2017.04.015_bib124","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase a reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2017.04.015_bib125","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib126","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions","volume":"7","author":"Alfadhel","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.cjca.2017.04.015_bib127","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib128","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib129","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2017.04.015_bib130","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.04.015_bib131","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2362.2011.02614.x","article-title":"Interdisciplinary approach towards female patients with Fabry disease","volume":"42","author":"Weidemann","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cjca.2017.04.015_bib132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib133","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.113.002799","article-title":"Progression of Fabry cardiomyopathy despite enzyme replacement therapy","volume":"128","author":"Pieroni","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.04.015_bib134","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/clc.22047","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"35","author":"Acharya","year":"2012","journal-title":"Clin Cardiol"},{"issue":"suppl 3","key":"10.1016\/j.cjca.2017.04.015_bib135","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1007\/s10545-010-9194-3","article-title":"Case report: long-term outcome post-heart transplantation in a woman with Fabry's disease","volume":"33","author":"Verocai","year":"2010","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.cjca.2017.04.015_bib136","doi-asserted-by":"crossref","first-page":"e15033","DOI":"10.1371\/journal.pone.0015033","article-title":"Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease","volume":"5","author":"Marshall","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2017.04.015_bib137","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol Med"},{"key":"10.1016\/j.cjca.2017.04.015_bib138","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"Aav2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase a and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2017.04.015_bib139","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0537900100","article-title":"Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer","volume":"100","author":"Park","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2017.04.015_bib140","doi-asserted-by":"crossref","first-page":"13777","DOI":"10.1073\/pnas.222221899","article-title":"Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer","volume":"99","author":"Takahashi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2017.04.015_bib141","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/mt.2012.64","article-title":"Lentivector transduction improves outcomes over transplantation of human HSCS alone in NOD\/SCID\/Fabry mice","volume":"20","author":"Pacienza","year":"2012","journal-title":"Mol Ther"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17302076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17302076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T06:18:29Z","timestamp":1569219509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X17302076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0828282X17302076"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2017.04.015","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Features, Diagnosis, and Management of Patients With Anderson-Fabry Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2017.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}